QIAGEN therascreen FGFR RGQ RT-PCR Kit
QIAGEN GmbH · Decision date May 6, 2026
What did the FDA approve?
FDA records P180043/S010 as a supplement to PMA P180043, with the supplement type “Real-Time Process”. The recorded decision is approval, dated May 6, 2026.
FDA approval order statement
Approval for a minor material change which would replace the BSA (Bovine Serum Album) in the PCR Master Mix tubes with a recombinant Human Serum Albumin (rHSA).
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Medical Genetics
- Decision date
- May 6, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P180043/S010
- Regulatory pathway
- PMA supplement
- Applicant
- QIAGEN GmbH
- Product code
- OWD
- Decision code
- APPR
- Decision date
- May 6, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Somatic gene mutation detection system.
- Applicant
- QIAGEN GmbH
- Product code
- OWD
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P180043/S007 · Related supplement
QIAGEN therascreen FGFR RGQ RT-PCR Kit
P180043/S010 received
Application receipt date recorded by FDA.
P180043/S010 · FDA decision
Real-Time Process
Timeline entries are records held by MedtechLedger for P180043. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P180043
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
QIAGEN therascreen FGFR RGQ RT-PCR KitP180043/S007 | QIAGEN GmbH | PMA supplement | Oct 3, 2025 | FDA |
Explore the linked device profile
Other records with product code OWD
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Roche cobas BRAF V600 Mutation TestP110020/S046 | Roche Molecular Systems, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Roche cobas EGFR Mutation Test, v2.0P120019/S045 | Roche | PMA supplement | Nov 4, 2026 | FDA |
Roche cobas KRAS Mutation TestP140023/S034 | Roche Molecular Systems, Inc. | PMA supplement | Nov 4, 2026 | FDA |
cobas BRAF V600 Mutation TestP110020/S045 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
cobas EGFR Mutation Test, v2.0P120019/S044 | Roche | PMA supplement | Oct 27, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
QIAGEN GmbH
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Qiagen Strasse 1, Hilden, 40724
Sources and methodology
- Original FDA record: P180043/S010
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




